Bio

John joined Aquilo Partners in 2009 from JP Morgan, where he was an Executive Director in the healthcare investment banking group. Joining JP Morgan in 2006, John advised public and private biotechnology clients on a wide range of strategic and financing engagements. From 2000 to 2006, John was a member of the healthcare investment banking group at Cowen and Company in New York and San Francisco, where he focused on small and mid-cap public and private biotechnology clients. His experience includes partnering, sellsides, acquisitions, divestitures, IPOs and follow-on offerings in the biotechnology, specialty pharma and diagnostics sectors. Prior to joining Aquilo, John’s advisory transaction experience includes Medivation’s collaboration with Pfizer, Myriad Genetics’ spin-off of its pharmaceutical business and Agensys’ sale to Astellas. John also led financings for Seattle Genetics, Genomic Health, Array BioPharma, Myriad Genetics and MannKind. John received a Masters in International Business Administration from the Moore School of Business at the University of South Carolina, where he graduated Beta Gamma Sigma, and a BA from the University of Virginia. In July 2012, John opened Aquilo’s office in Cambridge, MA.